The source stays close to the claim.
Here are the papers and public records behind the articles. The notes explain why each source is here. You can follow a claim back to what was studied.
Read the setting with the result
A receptor experiment explains an interaction. A human trial tests a question in particular people. A review brings several studies together. The source type matters as much as the interesting phrase in its title.
With FDA records, we keep the date and the right table in view. A withdrawn compounding nomination and a safety-concern listing aren't interchangeable. Neither is a drug approval.
The source is easier to read when you know which question you're bringing to it.
Mechanisms and human findings
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
Animal-heavy healing research and small human reports. Stronger human trials are still needed.
BPC157 and VEGFR2 activation
Blood-vessel findings in animals and cultured human cells. These aren't human recovery results.
Safety of Intravenous Infusion of BPC157 in Humans
Two adults, no observed side effects. Too small to establish safety or healing.
Ipamorelin, the first selective growth hormone secretagogue
Early animal hormone research. Selectivity describes the measured responses, rather than general safety.
Ipamorelin exposure and growth hormone response in human volunteers
A hormone response after an infusion into a vein. No sleep or recovery test.
Ipamorelin after bowel resection
A controlled surgery trial. No convincing difference in how soon patients tolerated a meal.
Structural insights into retatrutide’s triple agonism
One peptide, three receptors. These molecular interactions aren't themselves a clinical outcome.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity
Weight loss, digestive effects and heart-rate increases. Group results aren't personal forecasts.
Retatrutide—A Game Changer in Obesity Pharmacotherapy
The triple-receptor design and early trials. The enthusiastic title isn't an approval decision.
Thymosin alpha 1: A comprehensive review of the literature
Background on thymosin alpha-1 and its clinical research. This review predates the larger sepsis trial.
A Reappraisal of Thymosin Alpha1 in Cancer Therapy
Immune activation and regulation. These mechanisms don't prove a cancer-treatment benefit or a broad immunity claim.
Thymosin alpha1 for sepsis: the TESTS trial
No clear reduction in deaths by day 28 in a large sepsis trial. Manufacturer support and author financial ties were declared.
A study of biology doesn't decide approval or lawful access. Those questions need different records.
Safety reviews and the access boundary
FDA review of ipamorelin-related bulk substances
Surgical deaths with uncertain causation and other safety concerns. No safety studies for injections under the skin.
FDA presentation on thymosin alpha-1-related substances
Reported injection-site effects, ingredient quality and possible immune reactions. Biological effects don't answer these safety questions.
Bulk substances that may present significant safety risks
Withdrawn nominations and Category 2 are separate tables. Ipamorelin acetate has a distinct 503B safety-concern listing.
FDA concerns with unapproved GLP-1 drugs
FDA says retatrutide cannot be used in compounding under federal law. A research label doesn't change that.
Compounding and FDA: questions and answers
Why a prescription and FDA approval are different. Compounded drugs don't receive FDA's approval review.
Compounded drugs aren't FDA-approved. A prescription doesn't change that distinction. The comparison connects these records with the different questions on each compound page.